- Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer discovery. 2017 In Process GET IT
- Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer discovery. 2014 Academic Article GET IT
- A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nature genetics. 2013 Academic Article GET IT
Subtle variations in Pten dose determine cancer susceptibility.
Times cited: 277
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.
The Journal of clinical investigation.
Times cited: 146